Caricamento...
Is There a Path Forward for mGlu(2) Positive Allosteric Modulators for the Treatment of Schizophrenia?
Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia. The first outcome revealed that Eli Lilly’s mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point. The second report showed the...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Chemical
Society
2013
|
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3582287/ https://ncbi.nlm.nih.gov/pubmed/23421671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cn400023y |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|